Back to Agenda
New Approaches, Novel Endpoints, and Next-Generation Trials
Session Chair(s)
Jennifer Goldsack, MA, MBA, MS
Chief Executive Officer
Digital Medicine Society (DiMe), United States
Using a case study, we will illustrate CTTI recommended practices for selecting, developing, and including technology-derived endpoints in regulatory trials. Participants can apply best practices learned to other scenarios, including their own work.
Learning Objective : Describe approaches to identifying mobile technology-derived outcome measures that are most valuable and warrant development; Review approaches for optimizing the efficiency of technology-derived novel endpoint development; Discuss how to include and position technology-derived novel endpoints to be most impactful.
Speaker(s)
![Jessie Bakker, PhD, MS](/_Images/member/Generic_Image_Missing-Profile.jpg)
Facilitator
Jessie Bakker, PhD, MS
Digital Medicine Society (DiMe), United States
Vice President of Digital Measures and Diagnostics
![Daniel Rollings Karlin, DrMed, MA, FAPA](/_Images/member/Generic_Image_Missing-Profile.jpg)
Facilitator
Daniel Rollings Karlin, DrMed, MA, FAPA
MindMed, United States
Chief Medical Officer
![Komathi Stem, MS](/_Images/member/Generic_Image_Missing-Profile.jpg)
Facilitator
Komathi Stem, MS
Glooko, United States
Chief Operating Officer
Have an account?